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Table 1 Baseline Characteristics of the Total Cohort
Characteristics
HSP27 <3,503 pg/ml
(n ¼ 65)
HSP27 >3,503 pg/ml
(n ¼ 64)
Age, yrs 62.0  12.4 59.3  11.6
Males 42 (64.6) 34 (53.1)
Hypertension* 33 (50.8) 23 (35.9)
Diabetes* 20 (30.8) 16 (25.0)
Dyslipidemia* 36 (55.4) 27 (42.2)
Smoking 19 (29.2) 14 (21.9)
Lipid proﬁle, mmol/l
Total cholesterol 4.0  1.1 4.8  1.3
LDL cholesterol 2.3  0.9 2.8  1.0
HDL cholesterol 1.2  0.3 1.2  0.5
Outcomes
Death 5 (8.7) 1 (1.6)
Myocardial infarction 12 (18.5) 4 (6.3)
Stroke 0 (0.0) 0 (0.0)
Values are mean  SD or n (%). *Patients had a clinical diagnosis by a treating physician.
HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein.
Abbreviations
and Acronyms
ApoE = apolipoprotein E
CAD = coronary artery
disease
HFD = high-fat diet
HSP27 = heat shock
protein 27
IL = interleukin
IQR = interquartile range
MACE = major adverse
cardiovascular event(s)
PBS = phosphate-buffered
saline
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1447have functional roles in the extracellular space (4,5). HSP27
is known to be a cytoprotective, antiapoptotic (6), and anti-
inﬂammatory protein (5,7,8).
Ubiquitous overexpression of HSP27 in atherosclerosis-
prone apolipoprotein (A) E/ mice reduced aortic plaque
burden in female, but not male, mice (9). The extent of
atheroprotection in these female mice was related to elevated serum
HSP27 levels that required intact ovarian function or exogenous
estrogenic hormone replacement therapy (9–11). In humans,
See page 1455
reduced levels of HSP27 have been recovered from the
secretome of atherosclerotic carotid endarterectomy samples
compared with control specimens; furthermore, HSP27
release from complicated plaques is reduced compared with
release from noncomplicated plaques (12). Finally, although
it has been reported in a small cohort that serum HSP27
levels are reduced in patients with carotid atherosclerosis
(12) and increased in those with acute coronary syndromes
(13), it remains unclear whether these levels correlate with
the angiographic presence of CAD or are indicative of future
events. Moreover, it is unclear whether increasing serum
HSP27 levels have therapeutic potential or whether HSP27,
like C-reactive protein (14) and homocysteine (15), is simply
a biomarker.
In the current study, we explored whether serum HSP27
levels are lower in patients with CAD compared with healthy
controls and whether these levels hold prognostic signiﬁ-
cance. We assessed whether increasing serum HSP27 is
a potential therapeutic target by treating female ApoE/
mice with HSP27 overexpressing bone marrow or recombi-
nant HSP27 (rHSP27) and subsequently evaluated de novo
atherosclerotic lesion formation. Finally, we examined
whether rHSP27 treatment can attenuate lesion progression
and enhance lesion remodeling.
Methods
For full details of the methods, please see the Online
Appendix.
Results
Serum HSP27 levels are lower in patients with CAD and
are predictive of future adverse cardiovascular events. To
establish whether serum HSP27 levels are lower in patients
with CAD, we prospectively enrolled 129 individuals
presenting for assessment for CAD from July 2006 to
February 2008. Baseline patient characteristics are outlined
in Table 1 and in Online Tables I and II. Low- and
intermediate-risk patients underwent coronary evaluation by
invasive angiography or computed tomography, and baseline
serum HSP27 levels were quantiﬁed by enzyme-linked
immunosorbent assay. Patients with >50% stenosis in any
major epicardial artery had lower HSP27 levels comparedwith those free of atheroscle-
rosis (median [interquartile range
(IQR)]: 2,176 pg/ml [551 to
5,475] vs. 6,200 pg/ml [2,575 to
9,560]; p < 0.001) (Fig. 1A).
Consistent with previous murine
studies (9–11), females had
higher HSP27 levels than males
(median [IQR]: 6,175 pg/ml
[747 to 9,800] vs. 2,779 pg/ml
[1,130 to 5,793]; p ¼ 0.049]
(Fig. 1B), although in CAD
patients, HSP27 levels were
markedly lower in both sexes
(p ¼ 0.02 for females; p < 0.01
for males). To determine whether serum HSP27 levels are
predictive of future cardiovascular events, patients were fol-
lowed for subsequent myocardial infarction, stroke, or death
(major adverse cardiovascular events [MACE]). Overall, the
time to event ranged from 24 to 1,852 days of follow-up,
with the median being 828 days (IQR: 356 to 1,092 days).
Patients in the lower 50th percentile of serum HSP27 levels
had a markedly higher risk of MACE (hazard ratio: 2.93;
95% conﬁdence interval: 1.06 to 8.12; p ¼ 0.04) (Fig. 1C).
As well, within the cohort of patients with CAD at baseline,
patients in the lower 50th percentile of serum HSP27 levels
showed a strong trend toward a higher risk of MACE
(hazard ratio: 3.08; 95% conﬁdence interval: 0.99 to 9.52;
p ¼ 0.05) (Fig. 1D). Thus, in humans, lower serum HSP27
levels are not only associated with the presence of disease but
also are prognostic of future adverse clinical events.
Blood-borne HSP27 is sufﬁcient for atheroprotection.
Previously we demonstrated that the ubiquitous overexpression
of HSP27 in female ApoE/ mice, which do not have the
geneHSPB1, which encodes forHSP27, was protective against
the development of atherosclerosis (9). The atheroprotective
effects appeared to be related to elevated serum HSP27 levels
Figure 1 Serum HSP27 Levels Are Lower in Patients With CAD and Are Predictive of Future Cardiovascular Events
(A) Patients with coronary artery disease (CAD) (n ¼ 76) have lower baseline levels of serum heat shock protein 27 (HSP27) than controls (n ¼ 53). (B) Comparison of female
and male levels of serum HSP27. Upper and lower limits of the box plot demarcate the 75th and 25th percentiles, respectively. Median and mean are represented by the
horizontal line and diamond, respectively. (C, D) The total cohort and patients with obstructive CAD were stratiﬁed into upper and lower 50th centiles and major adverse
cardiovascular events reported out to 5 years. Vertical dashes indicate censuring of patients lost to follow-up. HR ¼ hazard ratio.
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1448that required intact ovarian function or exogenous estrogenic
hormones (10,11). However, it remained unclear whether
serum or vascular tissue HSP27 levels were responsible for
atheroprotection. Because we previously demonstrated the
secretion of HSP27 from macrophages (9,10), we sought to
determine whether nonvascular sources of increased serum
HSP27 would protect against atherosclerosis. Bone marrow
from 10-week-old female ApoE/HSP27o/e mice was
transplanted into 10-week-old female ApoE/ littermates,
which do not have the gene HSPB1, which encodes for
HSP27. The effect on atherogenesis was compared with
that in a control group in which 10-week-old female
ApoE/ bone marrow was transplanted into 10-week-old
female ApoE/ littermates (Fig. 2A). Mice were allowed
to recover from the transplantation for 6 weeks before being
fed an atherogenic diet (high-fat diet [HFD]: 15.8% fat and
1.25% cholesterol) for 4 weeks. No signiﬁcant differences
were found in the mean body weights of the 2 transplant
groups (data not shown). As expected, serum HSP27 levels
were undetectable in the control group (ApoE/ bone
marrow recipients, n ¼ 10) (Fig. 2B). In contrast, trans-
plantation of bone marrow from ApoE/HSP27o/e mice
(n ¼ 8) resulted in serum HSP27 levels of 588  203 pg/ml
(Fig. 2B). Despite no obvious differences in total serum
cholesterol levels between the 2 groups (p ¼ 0.219)
(Fig. 2C), mice receiving ApoE/HSP27o/e bone marrow
showed reductions in aortic lesion burden in both en face
(50%; p ¼ 0.002) (Fig. 2D) and aortic sinus lesions (28%;
p¼ 0.002) (Figs. 2E and 2F). In addition to decreased aorticlesion burden in the ApoE/HSP27o/e transplant recipi-
ents, the area occupied by cholesterol clefts and the necrotic
core area were decreased, without differences in lesion
macrophage area (p ¼ 0.457) (Figs. 2E and 2F). Finally,
there was a 59% decrease in the terminal deoxynucleotidyl
transferase–mediated dUTPnick end labeling assay–positive
intimal cell area in mice that received ApoE/HSP27o/e
bone marrow compared with the ApoE/ controls
(p ¼ 0.007) (Figs. 2G and 2H). Thus, increasing serum
HSP27 through overexpression from nonvascular tissues
is sufﬁcient to attenuate de novo atherosclerotic lesion
formation in atheroprone mice, suggesting a potential
therapeutic beneﬁt.
Therapeutic administration of rHSP27 attenuates the
progression of atherogenesis. Recent studies have high-
lighted the importance of differentiating genuine therapeutic
targets from biomarkers of disease (14,15). Given the
observation in humans that CAD is associated with low
serum HSP27 levels and the atheroprotection afforded by
increasing serum HSP27 levels in overexpressing models (9),
we synthesized rHSP27 to explore its potential therapeutic
effects in de novo lesion formation. Seven-week-old female
ApoE/ mice were randomized to receive subcutaneous
injections of either rHSP27 (100 mg) or vehicle (phos-
phate-buffered saline [PBS]) twice daily while being
maintained on an atherogenic diet (HFD: 15.8% fat and
1.25% cholesterol), for 3 weeks (Fig. 3A). Serum HSP27
levels were detectable by enzyme-linked immunosorbent
assay after the subcutaneous injection, with a peak serum
Figure 2 Blood-borne HSP27 Is Sufﬁcient for Atheroprotection
(A) Experimental overview: 10-week-old female apolipoprotein (Apo) E/mice were lethally irradiated and transplanted with bone marrow cells from ApoE/HSP27o/e or ApoE/
littermates andallowed to recover for6weeks.Micewere thenplacedonanatherogenic diet (high-fat diet, 15.8% fat and1.25%cholesterol) for4weeks toaccelerateatherosclerosis.
(B)End-of-study serumheat shock protein 27 (HSP27) levels. HSP27 is present in the serum ofmice receiving ApoE/HSP27o/e bonemarrow but not ApoE/ bonemarrow. (C)No
difference in total serum cholesterol was observed between the groups at the end of the study (p ¼ 0.2). (D) Expression of HSP27 by bone marrow–derived hematopoietic cells
reduces en face atherosclerotic lesion size in ApoE/mice. Quantiﬁcation of lesion area/total aortic arch area revealed a 50% reduction in lesion burden in ApoE/mice receiving
ApoE/HSP27o/e bone marrow (p ¼ 0.002). (E, F) Expression of HSP27 by bone marrow–derived cells reduces lesion size in the aortic sinus of ApoE/ mice. Quantiﬁcation of
aortic sinus lesionarea revealed a28% reduction in lesion burden in ApoE/mice receiving ApoE/HSP27o/e bonemarrow (p¼0.002). Transplantation of ApoE/HSP27o/e bone
marrow reduced the cholesterol cleft areaof aortic sinus lesionsby23%relative tomice receiving theApoE/ bonemarrow (p¼0.002). (G,H)ExpressionofHSP27by bonemarrow–
derived cells reduces the terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling (TUNEL) assay–positive area within aortic sinus lesions of ApoE/ mice. Quan-
tiﬁcation of aortic sinus TUNEL-positive cell area revealed a 59% reduction in apoptosis in ApoE/ mice receiving ApoE/HSP27o/e bone marrow (p ¼ 0.007).
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1450concentration of 219 ng/ml ( 62 SEM) after 80 min
(Online Fig. 1). As expected, serum HSP27 levels in the
vehicle control group (PBS injection) were not detectable
(data not shown), as ApoE/ mice do not endogenously
express HSP27. Body weight remained stable and similar
between groups (data not shown). Treatment with rHSP27
reduced total aortic lesion area by 31% and 40% for the en
face and the sinus tissue preparations, respectively (p ¼ 0.003
and p ¼ 0.002) (Figs. 3B and 3C). Interestingly, total serum
cholesterol levels were 42% lower with rHSP27 treatment
(p < 0.001) due to reductions in very-low-density lipoprotein
and intermediate-IDL/low-density subfractions (Figs. 3D
and 3E).
Therapeutic administration of rHSP27 promotes morpho-
logical features of plaque stability in the settingof established
atherosclerosis. Clinical therapies are routinely initiated in
patients with established disease after events such as
myocardial infarction and stroke. Thus, we tested the ability of
rHSP27 to modulate the progression and morphology of
established atherosclerotic lesions. ApoE/micemaintained
on an atherogenic diet (HFD: 15.8% fat and 1.25% choles-
terol) to accelerate atherosclerosis for 4 weeks (designatedFigure 3 Administration of rHSP27 Attenuates Atherogenesis in Fem
(A) Experimental overview: female ApoE/ mice maintained on an atherogenic diet (HFD,
subcutaneous (b.i.d., s.c.) injections of recombinant heat shock protein 27 (rHSP27) (10
receiving rHSP27 show a 31% reduction in aortic lesion burden (p ¼ 0.003). Representa
quantiﬁcation (stained area expressed as a percentage of total arch area). (C) ApoE/ mi
Representative photos of Masson’s trichrome staining of the aortic sinus tissue cross se
total serum cholesterol levels by 42% (p  0.001) and (E) results in reduced cholesterol
low-density lipoprotein (LDL) subfractions. FPLC ¼ fast protein liquid chromatography; HDas the baseline atherosclerotic state) were switched to a normal
chow diet to simulate lipid management strategies such as
lifestyle modiﬁcations and/or clinical interventions such as
statin therapy. They then began subcutaneous injections of
either rHSP27 (100 mg) or PBS twice daily for 3 weeks
(Fig. 4A). Total serum cholesterol levels were similar in both
groups at baseline (PBS: 1,675  122 mg/dl vs. rHSP27:
1,706  103 mg/dl). Levels decreased 5- and 7-fold after
a switch to chow diet in the vehicle and therapy arms,
respectively, yet were 27% lower with rHSP27 treatment at
the time of euthanasia (PBS: 335  18 mg/dl vs. rHSP27:
243  17 mg/dl; p ¼ 0.004) (Fig. 4B).
Aortic lesion area was reduced by 20% and 24% on en face
and sinus cross-sectional analyses in rHSP27- vs. PBS-
treated mice (p ¼ 0.008 and p ¼ 0.001; respectively)
(Figs. 4C and 4D) and comparable to baseline (p ¼ 0.21).
Moreover, compared with PBS-treated mice, the intimal
plaque areas of mice receiving rHSP27 treatment had fewer
macrophages (reﬂected by anti-Mac-2 immunolabeling), less
free cholesterol accumulation (reﬂected by ﬁlipin staining),
and less area occupied by cholesterol clefts (Fig. 4E). Of note,
the role of cholesterol crystals in plaque inﬂammation wasale ApoE/ Mice
15.8% fat and 1.25% cholesterol) to accelerate atherosclerosis, received twice-daily
0 mg) or control (phosphate-buffered saline [PBS]) for 3 weeks. (B) ApoE/mice
tive photos of aortic en face lesions stained with oil red O followed by lesion
ce receiving rHSP27 show a 40% reduction in aortic sinus lesion burden (p ¼ 0.002).
ctions followed by lesion quantiﬁcation. (D) rHSP27 treatment reduces end-of-study
in the very-low-density lipoprotein (VLDL) and intermediate-density lipoprotein (IDL)/
L = high-density lipoprotein; other abbreviations as in Figure 2.
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1451recently linked to activation of the inﬂammasome with
subsequent interleukin-1b (IL-1b) production (16) and is
consistent with our previous observation that extracellular
HSP27 reduces acetylated LDL–induced increase in IL-1b
secretion from macrophages (9). Finally, rHSP27 treatment
was associated with more abundant collagen and smooth
muscle content as reﬂected by Picrosirius red staining and
a-smooth muscle actin immunolabeling compared with
lesions in PBS-treated micedhistological features consistent
with enhanced plaque stability in humans (17) (Fig. 4E).
Discussion
HSP27 expression is diminished in advanced human coro-
nary artery atherosclerotic lesions, and ubiquitous over-
expression of HSP27 in female mice reduces aortic plaque
burden to a degree that is proportional to the increase in
serum HSP27 levels (3,9–11). However, it remained unclear
whether human serum HSP27 levels correlated with disease
presence. In the current study, we identiﬁed a strong rela-
tionship between serum HSP27 levels and CAD in humans,
demonstrating that, similar to mouse studies, lower levels
correlate with more advanced disease. Moreover, we found
that patients with lower serum HSP27 had a markedly
higher risk of MACEdsuggesting that low HSP27 levels
correlate with disease severity or ongoing atherogenesis, thus
indicating that HSP27 may act as both a biomarker and
potential therapeutic target. To test this hypothesis we used
2 distinct mouse atherosclerosis models in which serum
levels of HSP27 were increased either by expression from
bone marrow–derived cells or exogenous administration. In
both models, increasing serum HSP27 levels attenuated the
development of de novo atherosclerotic lesions and shifted
plaques to a more stable morphology.
Few studies have delineated the relationship between
HSP27 and atherosclerosis in humans. Martin-Ventura et al.
(12,18) demonstrated in a small atherosclerotic group
(n ¼ 28) that the secretion of HSP27 from the vascular wall
diminishes as plaque complexity increases, and serum HSP27
levels are lower than those found in healthy controls (n ¼ 12).
Yet, the same group noted no relationship between serum
HSP27 levels and the development of ischemic myocardial or
cerebrovascular complications in a prospective case-control
study of apparently healthy middle-age women from the
WHS (Women’s Health Study) (19). However, there are
important differences in both the populations examined and
the study design between the WHS and the current study.
First, the WHS identiﬁed participants based on the occur-
rence of cardiovascular events (approximately half of which
were strokes) and controls as individuals free of these events.
In contrast, the current study used an angiographic deﬁnition
for the absence of coronary disease, removing the potential for
undiagnosed controls contaminating results.
Moreover, the prognostic signiﬁcance of lower serum
HSP27 levels within the cohort further validates our ﬁnd-
ings, suggesting that a dose response to serum HSP27 levelscan be identiﬁed in the natural history of CAD. Second, we
did not limit our study to women. Given the role that
estrogen and ovarian function plays in the extracellular
release of HSP27 (9,10), sex differences in these studies may
be important. This is an issue that we aim to address in
future studies with larger patient cohorts.
Although the potential prognostic value of serum HSP27
levels in humans may be clinically relevant, it does not
address whether increasing HSP27 levels is sufﬁcient to
prevent or stabilize atherosclerosis. Earlier studies (9) and
the current human data suggest a potential vascular beneﬁt
to increasing serum HSP27 levels; thus, we used 2 distinct
experimental mouse models in which serum HSP27 levels
were increased by endogenous nonvascular expression or by
exogenous administration of rHSP27 to determine the effect
of increasing serum HSP27 on atherogenesis.
Transplantation of HSP27-overexpressing bone marrow
(ApoE/HSP27o/e) to ApoE/ mice increased serum
HSP27 levels as well as reduced the burden of atherosclerosis
whenmicewere fed an atherogenic diet for 4weeks. The aortic
lesions in mice that were recipients of ApoE/HSP27o/e
bone marrow had fewer apoptotic intimal cells, less area
occupied by cholesterol clefts, and smaller necrotic cores,
despite no changes in total serum cholesterol. Given that
atheroprotective effects independent of changes in lipid
levels have been documented in the experimental athero-
sclerosis literature (20,21), it may be the case that in this
model, HSP27 has atheroprotective effects that are inde-
pendent of changes in total serum cholesterol.
In our second model, we synthesized rHSP27 to deter-
mine whether achieving higher serum levels by exogenous
administration would be sufﬁcient for atheroprotection. In
these studies, we observed that injection of rHSP27 twice
daily increased serum HSP27 levels while similarly reducing
the progression of atherosclerosis when mice were fed an
atherogenic diet for 3 weeks, thus conﬁrming that increasing
serum HSP27 levels alone could exert therapeutic effects.
Finally, as clinical therapies to prevent atherogenesis are
typically reserved for adult patients in whom atherosclerotic
disease is already present, we tested the ability of rHSP27 to
modulate the progression of established atherosclerotic
lesions (achieved by feeding mice an atherogenic diet for 4
weeks). Our results indicate that not only could rHSP27
administrations attenuate the further progression of lesions
in female ApoE/ mice, but also that it decreased the area
occupied by cholesterol clefts, free cholesterol, and macro-
phages. These observations are important because choles-
terol crystals have been implicated in plaque inﬂammation
through activation of the inﬂammasome and subsequent IL-
1b production (16). Similarly, we previously demonstrated
that extracellular HSP27 reduced the acetylated low-density
lipoprotein–induced increase in IL-1b secretion from
macrophages (9), suggesting that HSP27 therapy may have
the capacity to dampen vascular inﬂammation.
Study limitations. It is important to note that our study is not
without limitations. First, although human studies provide
Figure 4
rHSP27 Attenuates the Progression of Established Atherosclerotic Lesions and Promotes Morphological Features of
Plaque Stability
(A) Female ApoE/ mice were fed an atherogenic diet HFD, 15.8% fat and 1.25% cholesterol) for 4 weeks to accelerate atherosclerosis. Mice were then switched to chow and
received rHSP27 (100 mg) or PBS (control) b.i.d., s.c. for 3 weeks. (B) After cessation of HFD, total cholesterol levels decreased in both the PBS- and rHSP27-treated mice but
were 27% lower in the mice receiving rHSP27 (p ¼ 0.004). (C) ApoE/ mice receiving rHSP27 showed a 20% reduction in en face lesion area (p ¼ 0.008). Representative
photographs of aortic lesions stained with oil red O followed by lesion quantiﬁcation. (D) ApoE/ mice receiving rHSP27 showed a 24% reduction in aortic sinus area
(p ¼ 0.001). Representative photographs of Masson’s trichrome staining of aortic root cross sections followed by lesion quantiﬁcation. (E) HSP27 treatment decreases intimal
lesion cholesterol cleft area (Masson’s trichrome), free cholesterol accumulation (ﬁlipin staining), and macrophage content (Mac-2 immunolabeling). In contrast, rHSP27
treatment is associated with more abundant collagen and smooth muscle content (picrosirius red and a-smooth muscle actin [aSMA] immunolabeling, respectively) compared
with lesions in PBS-treated mice. Rx ¼ treatment; other abbreviations as in Figures 2 and 3.
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1452compelling evidence that links HSP27 levels to CAD and
prognosis, the current cohort is too small to fully adjust for
known confounding variables and thus precludes a robust
assessment of serumHSP27 as a biomarker. Nonetheless, this
represents the largest and most thorough evaluation of serum
HSP27 to date providing long-term follow-up on patients with
angiographically conﬁrmeddisease. Larger ongoing studieswill
address the performance of serum HSP27 as a biomarker.
Second, there is evidence that in certain types of cancer,
the inhibition of HSP27 may be a desirable therapeutic
target (22). However, this dichotomous nature of HSP27’srole in cancer versus cardiovascular disease is analogous to
one in which the goal in a cancer setting is to reduce tumor
neovessels that contribute to metastatic spread of a cancer
using antivascular endothelial growth factor strategies (23),
whereas pro–vascular endothelial growth factor strategies
have been used to enhance neovessels in the setting of
atherosclerotic cardiovascular disease (24). Likewise, although
the high expression of HSP27 in cancer is thought to be
deleterious and therapies aim to inhibit HSP27 expression
(25), the high expression of HSP27 is thought to be beneﬁcial
in neurodegenerative disease (26) and cardiac ischemia (27).
Figure 4 Continued
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1453Third, there are important potential limitations for trans-
lational development (i.e., long-term rHSP27 could induce an
immune response leading to adverse reactions to the therapy
or attenuated activity). However, in our extensive animal
studies to date, we have not observed any such consequences.
Fourth, although the current data provide proof-
of-concept validation of serum HSP27 levels as a thera-
peutic target, we are still working out the details as to how
HSP27 reduces atherosclerotic burden. Finally, accelerated
models of atherogenesis such as those used in the current
studies may not fully represent the human condition.
However, we do note that overexpression of HSP27 in
ApoE/ mice fed normal chow for 32 weeks also lowers
serum cholesterol levels and atherosclerotic burden (OnlineFig. 2). To our knowledge, we are the ﬁrst to describe the
phenomenon that HSP27 lowers serum cholesterol levels
and are pursuing several hypotheses that could help to
elucidate the putative mechanism(s) underlying these
observations. We know that rHSP27 is able to stimulate
signal transduction pathways in macrophages (8); hence,
there is the possibility that HSP27 could affect key enzymes
involved in lipid metabolism. For example, rHSP27 can
induce the expression and secretion of granulocyte-
macrophage colony-stimulating factor from macrophages
(8) and granulocyte-macrophage cerebrospinal ﬂuid can
lower serum cholesterol levels in humans and rabbits
(28–33). Alternatively, HSP27 may alter cholesterol levels
by binding to lipid moieties and, via its chaperone
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1454characteristics, alter the trafﬁcking of cholesterol, resulting
in increased clearance.
Conclusions
Our study is the ﬁrst prospective human cohort study to
establish a link between advanced atherosclerotic disease,
serum HSP27 levels, and prognosis of adverse vascular events.
We successfully demonstrated that elevation of serum HSP27
by either endogenous expression from nonvascular tissue or
therapeutic administration is sufﬁcient to prevent de novo
lesion formation and stabilize developed atherosclerotic
lesions. The current study serves as a proof-of-concept that
serumHSP27 may be a bona ﬁde therapeutic target for CAD.Reprint requests and correspondence: Dr. Edward O’Brien,
Division of Cardiology, Libin Cardiovascular Institute of Alberta,
Room C823, Foothills Medical Centre, 1403 29th Street NW,
Calgary, Alberta T2N 2T9, Canada. E-mail: ed.obrien@
albertahealthservices.ca.REFERENCES
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